9:01 AM ET
8-K
Licensing Deal
Tempus AI Licensing Deal with Bristol-Myers Squibb Company Worth $192M
Tempus AI entered into a series of agreements with Bristol-Myers Squibb (BMS) and Pathos AI to expand the use of its de-identified multimodal real-world data and analysis tools. The deal provides for aggregate cash payments to Tempus of $192.5 million over approximately five years, including $137.5 million for oncology data services to BMS and $55 million for neurology data and agentic tools to Pathos to support BMS's therapeutic development.
- Value
- $192M
- Counterparty
- Bristol-Myers Squibb Company
- Term
- 5 years